RU2005107414A - Генная терапия критической ишемии конечностей с использованием эндотелиальной синтазы оксида азота (enos) дикого типа или мутантной - Google Patents
Генная терапия критической ишемии конечностей с использованием эндотелиальной синтазы оксида азота (enos) дикого типа или мутантной Download PDFInfo
- Publication number
- RU2005107414A RU2005107414A RU2005107414/13A RU2005107414A RU2005107414A RU 2005107414 A RU2005107414 A RU 2005107414A RU 2005107414/13 A RU2005107414/13 A RU 2005107414/13A RU 2005107414 A RU2005107414 A RU 2005107414A RU 2005107414 A RU2005107414 A RU 2005107414A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- mutation
- enos
- position corresponding
- enos polypeptide
- Prior art date
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title 3
- 230000015572 biosynthetic process Effects 0.000 title 1
- 230000003511 endothelial effect Effects 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 208000028867 ischemia Diseases 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 43
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 claims 33
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 claims 33
- 229920001184 polypeptide Polymers 0.000 claims 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims 33
- 230000035772 mutation Effects 0.000 claims 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 125000000539 amino acid group Chemical group 0.000 claims 16
- 238000006467 substitution reaction Methods 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 9
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 102000055702 human NOS3 Human genes 0.000 claims 5
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims 3
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 3
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102000000584 Calmodulin Human genes 0.000 claims 2
- 108010041952 Calmodulin Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000010060 microvascular dysfunction Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
- C12N9/0075—Nitric-oxide synthase (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40363702P | 2002-08-16 | 2002-08-16 | |
| US60/403,637 | 2002-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005107414A true RU2005107414A (ru) | 2006-01-27 |
Family
ID=31888259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005107414/13A RU2005107414A (ru) | 2002-08-16 | 2003-08-15 | Генная терапия критической ишемии конечностей с использованием эндотелиальной синтазы оксида азота (enos) дикого типа или мутантной |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040120930A1 (enExample) |
| EP (1) | EP1536689A4 (enExample) |
| JP (1) | JP2005539031A (enExample) |
| KR (1) | KR20050042162A (enExample) |
| CN (2) | CN101391105A (enExample) |
| AU (1) | AU2003263844A1 (enExample) |
| BR (1) | BR0313515A (enExample) |
| CA (1) | CA2494845A1 (enExample) |
| IL (1) | IL166362A0 (enExample) |
| MX (1) | MXPA05001763A (enExample) |
| NO (1) | NO20051351L (enExample) |
| PL (1) | PL375446A1 (enExample) |
| RU (1) | RU2005107414A (enExample) |
| WO (1) | WO2004016761A2 (enExample) |
| ZA (1) | ZA200502181B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014123749A1 (en) * | 2013-01-30 | 2014-08-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for treating complications associated with diabetes |
| US20190284263A1 (en) * | 2016-04-29 | 2019-09-19 | Inovio Pharmaceuticals, Inc. | In vivo use of chondroitinase and/or hyaluronidase to enhance delivery of an agent |
| CN105944243A (zh) * | 2016-05-12 | 2016-09-21 | 段俊丽 | 一种eNOS表达与活化的调控装置及周围动脉疾病的治疗装置 |
| KR20200013674A (ko) * | 2017-05-02 | 2020-02-07 | 유니버시티 오브 마이애미 | 허혈 조직을 치료하는 방법 |
| CN107802826B (zh) * | 2017-10-26 | 2020-02-18 | 首都医科大学宣武医院 | eNOS突变体在促进血管生成中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1061800A4 (en) * | 1998-03-09 | 2004-10-06 | Caritas St Elizabeths Boston | COMPOSITIONS AND METHODS FOR MODULATING THE VASCULARIZATION |
| EP1016726A1 (en) * | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
| WO2000062605A1 (en) * | 1999-04-16 | 2000-10-26 | Yale University | eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING |
-
2003
- 2003-08-15 JP JP2004529471A patent/JP2005539031A/ja active Pending
- 2003-08-15 BR BR0313515-2A patent/BR0313515A/pt not_active IP Right Cessation
- 2003-08-15 EP EP03788540A patent/EP1536689A4/en not_active Withdrawn
- 2003-08-15 CA CA002494845A patent/CA2494845A1/en not_active Abandoned
- 2003-08-15 WO PCT/US2003/025626 patent/WO2004016761A2/en not_active Ceased
- 2003-08-15 CN CNA2008101259592A patent/CN101391105A/zh active Pending
- 2003-08-15 PL PL03375446A patent/PL375446A1/xx not_active Application Discontinuation
- 2003-08-15 US US10/642,255 patent/US20040120930A1/en not_active Abandoned
- 2003-08-15 KR KR1020057002657A patent/KR20050042162A/ko not_active Ceased
- 2003-08-15 AU AU2003263844A patent/AU2003263844A1/en not_active Abandoned
- 2003-08-15 MX MXPA05001763A patent/MXPA05001763A/es not_active Application Discontinuation
- 2003-08-15 CN CNB038194945A patent/CN100408101C/zh not_active Expired - Fee Related
- 2003-08-15 RU RU2005107414/13A patent/RU2005107414A/ru not_active Application Discontinuation
-
2005
- 2005-01-18 IL IL16636205A patent/IL166362A0/xx unknown
- 2005-03-15 NO NO20051351A patent/NO20051351L/no not_active Application Discontinuation
- 2005-03-15 ZA ZA200502181A patent/ZA200502181B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1536689A4 (en) | 2006-09-06 |
| IL166362A0 (en) | 2006-01-16 |
| MXPA05001763A (es) | 2005-08-19 |
| JP2005539031A (ja) | 2005-12-22 |
| AU2003263844A1 (en) | 2004-03-03 |
| US20040120930A1 (en) | 2004-06-24 |
| EP1536689A2 (en) | 2005-06-08 |
| CA2494845A1 (en) | 2004-02-26 |
| NO20051351L (no) | 2005-04-28 |
| WO2004016761A3 (en) | 2005-03-17 |
| CN100408101C (zh) | 2008-08-06 |
| BR0313515A (pt) | 2005-10-18 |
| PL375446A1 (en) | 2005-11-28 |
| CN101391105A (zh) | 2009-03-25 |
| CN1688197A (zh) | 2005-10-26 |
| WO2004016761A2 (en) | 2004-02-26 |
| KR20050042162A (ko) | 2005-05-04 |
| ZA200502181B (en) | 2006-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI117667B (fi) | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä | |
| US7138374B2 (en) | Methods of using analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamate 89, asparate 101 or leucine 137 | |
| EP1778842B8 (en) | Compositions and methods of use for mgd-csf in disease treatment | |
| JP2007181465A (ja) | マクロファージ炎症蛋白変種をコードするポリヌクレオチド | |
| JPH0699322B2 (ja) | 傷の治癒 | |
| CA2362496C (en) | Polypeptide variants with increased heparin-binding ability | |
| Tepper et al. | Gene therapy in plastic surgery | |
| JP6025002B2 (ja) | 骨形成または血管新生促進用ペプチドｂｆｐ４およびその用途 | |
| CN113383012A (zh) | 人肝细胞生长因子突变体及其应用 | |
| JP2009502782A (ja) | 硬組織形成を促進するためのタンパク質製剤 | |
| CN101914561B (zh) | 一种具有抗菌和修复功能的融合蛋白及其生产方法和应用 | |
| KR920004571A (ko) | 헤파린 결합 향신경성 인자(hbnf)를 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, 및 hbnf의 생성 방법 및 사용방법 | |
| RU2005107414A (ru) | Генная терапия критической ишемии конечностей с использованием эндотелиальной синтазы оксида азота (enos) дикого типа или мутантной | |
| US8252738B2 (en) | Method for changing cell phenotype using LIM mineralization proteins | |
| JP2005539031A5 (enExample) | ||
| Schultheiss | Regenerative medicine in andrology: Tissue engineering and gene therapy as potential treatment options for penile deformations and erectile dysfunction | |
| WO2000021998A1 (en) | Bone morphogenetic protein antagonist based on the mature protein | |
| US9447155B2 (en) | Isoform Nell-1 peptide | |
| JP2007505621A (ja) | 骨誘導タンパク質及びペプチドの細胞内送達 | |
| CN100431611C (zh) | 多肽－脂质体与人血管内皮生长因子基因重组质粒复合物及用途 | |
| KR102301574B1 (ko) | Mbp-fgf2를 포함하는 골격근 줄기세포의 활성 또는 증식 강화용 조성물 | |
| MXPA00009440A (es) | Uso de factor de dispersion para mejorar angiogenesis. | |
| US20030148952A1 (en) | Methods and materials for the recruitment of endothelial cells | |
| JP4775663B2 (ja) | 血管新生制御方法 | |
| WO2005084691B1 (en) | Method of proliferating precursor cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090310 |